News and views

THE following names of scientific workers and others associated with scientific activities appear in the New Year's honours list, which, owing to the illness of His Majesty the King, was not issued until Mar. 1: Barons: Sir Jesse Boot, for services in the promotion of education; Sir Berkeley Moynihan, president of the Royal College of Surgeons. Knights: Prof. J. A. Fleming, emeritus professor of electrical engineering, University College, London; Mr. G. A. Julius, chairman of the Council for Scientific and Industrial Research, Commonwealth of Australia; Col. T. F. Purves, Engineer-in-Chief, Post Office; Mr. A. V. Roe, for distinguished services to British aviation; Sardar Jogendra Singh, Minister for Agriculture, Punjab; Lee ah Yain, Minister for Forests, Burma; Companion of Honour: Lady Florence Elizabeth Barrett, Dean of the London School of Medicine for Women and president of the Medical Women's International Association. C.B.: Sir Walter Morley Fletcher, secretary of the Medical Research Council; Dr. G. F. Hill, Keeper of the Department of Coins and Medals, British Museum. C.M.G.: Mr. F. C. Madden, Dean of the Faculty of Medicine, Egyptian University, Cairo. K.C.I.E.: Sir Thomas Middleton, lately member of the Royal Commission on Agriculture in India. C.I.E.: Mr. R. S. Finlow, Director of Agriculture, Bengal; Mr. N. N. Gangulee, lately member of the Royal Commission on Agriculture in India; Mr. J. A. Madan, lately joint secretary to the Royal Commission on Agriculture in India; Mr. W. Mayes, Chief Conservator of Forests, Punjab; Mr. F. W. H. Smith, lately joint secretary to the Royal Commission on Agriculture in India. G.B.E.: Sir William McCormick, chairman of the University Grants Committee and of the Advisory Council of the Department of Scientific and Industrial Research. D.B.E.: Prof. Anne Louise Mcllroy, professor of obstetrics and gynaecology, Royal Free Hospital School of Medicine for Women, University of London. C.B.E.: Prof. Winifred Cullis, professor of physiology, London (Royal Free Hospital) School of Medicine for Women; Mr. R. Hewison, late Director of Agriculture and Forests, Sudan Government; Mr. W. Nowell, Director of the Amani Research Institute, Tanganyika Territory. O.B.E.: Mr. G. E. Hunt, lecturer in engineering, Gordon College, Khartoum; Mr. W. A. Taylor, superintending examiner, Patent Office. M.B.E.: Mr. G. E. Holden, technical adviser to the Dyestuffs Advisory Licensing Committee; Mr. A. J. W. Hornby, agricultural chemist, Nyasaland Protectorate.

devices, and cell therapies. Cell therapy describes a process in which viable cells are introduced into the body to produce medicinal effects; cells may be derived from a cell bank (allogeneic cell therapy) or be patient-derived cells converted into the desired cell type or tissue in a lab (autologous cell therapy). Through the acquisition, development and commercialization of these assets, Healiva enters the billion-dollar wound-care market. To find out more, visit healiva.com.

| KERECIS
Kerecis, the company pioneering the use of fish skin and fatty acids in cellular therapy, tissue regeneration and protection, announced MariGen Expanse, the newest addition to Kerecis' product offerings for chronic wound management. The announcement was made at the Symposium for Advanced Wound Care (SAWC) meeting, which is taking place in the Phoenix Convention Center from April 6 to 10, 2022. Kerecis is exhibiting at booth 325.
This pre-meshed, intact-fish-skin graft supports healing and tissue regeneration in large chronic wounds especially wounds 100 square centimetres (15.5 square inches) and larger that are treated in an out-patient care setting. MariGen Expanse is an extension of Kerecis' MariGen product line, which has been used to successfully treat tens of thousands of patients, prevented multiple amputations and improved the quality of life for many people around the world.
Kerecis products are based on fatty-acid-rich, intact fish skin that, when grafted onto damaged human tissue, recruits the body's own cells and ultimately is converted into living tissue. Because no disease-transfer risk exists between cold-water fish and humans, the Kerecis fish skin is only gently processed and retains its similarity to human tissue. The gentle processing preserves the skin's original three-dimensional structure and maintains the skin's inherent natural strength, complexity and molecules (such as Omega3 and other fatty acids). Clinical studies have found that the Kerecis products heal wounds faster than other products.
In addition to the new MariGen product, the company offers three other product lines. GraftGuide addresses the management of burn injuries; SurgiClose and SurgiBind are designed to address surgical deficiencies.

| About Kerecis
Kerecis develops products from fish skin and fatty acids for cellular therapy, tissue regeneration and protection. The Kerecis intact fish skin protects the body's tissues and enables it to regenerate tissues. The Kerecis sprayable topical and oral formulations protect the body from bacterial and viral infections.
Kerecis is the only approved manufacturer of medical devices containing intact fish skin globally. It is the fastest-growing company and one of the top eight in the U.S. biologics-skin and dermal-substitute market, according to SmartTRAK Business Intelligence.
Kerecis is committed to the United Nations Sustainable Development Goals. The fish skin used in Kerecis products derives from wild and sustainable fish stock caught in pristine Icelandic waters and processed with 100% renewable energy in the town of Isafjordur, close to the Arctic Circle. For more information, visit https:// www.kerecis.com.

| AATRU MEDICAL
Aatru Medical, is pleased to announce a Latin America distribution agreement with Salus Biomedical, for the NPSIMS product. The product received recent FDA 510 (k) clearance, and Aatru is in the process of finalising market introduction plans. Initial markets include Latin America, with U.S. and additional global markets to follow.
The patented NPSIMS utilises a safe and innovative solid-state chemical reaction to create and apply negative pressure in the therapeutic range to closed incision sites for up to 7 days. The unique mode-of-action, which contains no moving parts or electromechanical components, delivers similar clinical performance to other available Negative Pressure Wound Therapy (NPWT) devices while providing substantial advantages in patient quality of life, ease of use, and price.
Several post-operative wound complications are common following surgical procedures. Negative pressure wound therapy (NPWT) is well recognised for the management of open wounds, and in the last several years has been applied to closed surgical incisions. Compared with standard postoperative dressings, NPWT has been clinically shown to significantly reduce the rate of surgical site infection and seroma.

| About Aatru medical
Aatru is a privately held medical device technology company focused on disrupting the surgical incision market with its FDA-cleared NPSIMS, a simple, disposable, single-use, patented, low-cost NPWT device, uniquely designed to require no electromechanical pump, battery or canister. More information can be found on the Aatru Medical, LLC website: www.aatru.com 4 | LIMFLOW 4.1 | LimFlow completes enrollment in PROMISE II U.S. pivotal trial of breakthrough device designed to prevent amputations in no-option patients with chronic limb-threatening ischemia LimFlow, a pioneer in the development of minimallyinvasive technology for the treatment of chronic limbthreatening ischemia (CLTI), a severe form of peripheral artery disease (PAD), announced that it has completed patient enrollment in the PROMISE II pivotal trial of the LimFlow System. The LimFlow System is designed to re-establish arterialization in deep veins for patients who have exhausted other methods and face major amputation of their lower limbs.
PROMISE II is a multi-center, prospective, single-arm study being conducted at multiple sites in the U.S. Using an adaptive statistical design, the study enrolled 105 nooption CLTI patients. Endpoints include amputation-free survival at 6 months, limb salvage and wound healing, and subjects will be followed out for 3 years. The nooption patients treated in PROMISE II were determined by an independent physician committee to be no longer eligible for conventional endovascular or surgical therapy to treat CLTI.
LimFlow also announced the completion of enrollment in the CLariTI study of approximately 200 high-risk and no-option CLTI patients. The prospective, observational, multicenter CLariTI study will track the clinical progression of CLTI and incidence of death, amputation, and revascularization attempts in patients undergoing standard medical management for the disease over a one-year period.
CLTI is the most severe form of PAD and often occurs in patients suffering from coronary artery disease, diabetes, obesity, high cholesterol and/or high blood pressure. Patients with CLTI often experience profound, chronic pain and develop festering wounds or infections that lead to major limb amputation, an event closely associated with increased mortality and reduced quality of life. To relieve the symptoms of CLTI, patients today are treated primarily with angioplasty or open bypass surgery. In many late-stage patients, however, neither option is feasible due to extensive disease in the target arteries or other anatomical constraints.
About LimFlow and the LimFlow System. LimFlow is a private, venture-backed medical device company transforming the treatment of chronic limbthreatening ischemia, a growing clinical need in the face of the prevalence of diabetes, heart disease, kidney disease and an aging population.
When all other therapeutic options have been exhausted and a CLTI patient is facing major amputation, the minimally invasive LimFlow system is designed to bypass blocked arteries in the leg and deliver oxygenated blood back into the foot via the veins. For many patients, restoring perfusion in the lower limbs resolves chronic pain, improves the quality of life, enables wound healing, and prevents major amputation.
For more information, visit www.limflow.com.
How to cite this article: News and views. Int Wound J. 2022;19 (5)